{"nctId":"NCT03720470","briefTitle":"Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","startDateStruct":{"date":"2018-10-29","type":"ACTUAL"},"conditions":["Dermatitis","Dermatitis, Atopic","Eczema","Skin Diseases","Skin Diseases, Genetic","Genetic Diseases, Inborn","Skin Diseases, Eczematous","Hypersensitivity","Hypersensitivity, Immediate","Immune System Diseases"],"count":838,"armGroups":[{"label":"PF-04965842 100 mg + Placebo Inj followed by PF-04965842 100mg","type":"EXPERIMENTAL","interventionNames":["Drug: PF-04965842 100 mg","Drug: Injectable Placebo"]},{"label":"PF-04965842 200 mg + Placebo Inj followed by PF-04965842 200mg","type":"EXPERIMENTAL","interventionNames":["Drug: PF-04965842 200 mg","Drug: Injectable Placebo"]},{"label":"Dupilumab Injection + Oral Placebo followed by Oral Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dupilumab","Drug: Oral Placebo"]},{"label":"Oral Placebo + Placebo Inj followed by 100 mg PF-04965842","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: PF-04965842 100 mg","Drug: Oral Placebo","Drug: Injectable Placebo"]},{"label":"Oral Placebo + Placebo Inj followed by 200 mg PF-04965842","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: PF-04965842 200 mg","Drug: Oral Placebo","Drug: Injectable Placebo"]}],"interventions":[{"name":"PF-04965842 100 mg","otherNames":[]},{"name":"PF-04965842 200 mg","otherNames":[]},{"name":"Dupilumab","otherNames":[]},{"name":"Oral Placebo","otherNames":[]},{"name":"Injectable Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects aged 18 years or older at the time of informed consent\n* Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (\\>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS severity 4)\n* Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with medicated topical therapy for AD for at least 4 weeks, or who have required systemic therapies for control of their disease.\n* Must be willing and able to comply with standardized background topical therapy, as per protocol guidelines throughout the study\n* Female subjects who are of childbearing potential must not be intending to become pregnant, currently pregnant, or lactating. The following conditions apply:\n\n  1. Female subjects of childbearing potential must have a confirmed negative pregnancy test prior to randomization;\n  2. Female subjects of childbearing potential must agree to use a highly effective method of contraception for the duration of the active treatment period and for at least 28 days after the last dose of investigational product.\n* Female subjects of non-childbearing potential must meet at least 1 of the following criteria:\n\n  * Have undergone a documented hysterectomy and/or bilateral oophorectomy;\n  * Have medically confirmed ovarian failure; or\n  * Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state.\n\nAll other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.\n\n-If receiving concomitant medications for any reason other than AD, must be on a stable regimen prior to Day 1 and through the duration of the study\n\nExclusion Criteria:\n\n* Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study\n* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator\n* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study\n* Other active nonAD inflammatory skin diseases or conditions affecting skin\n* Prior treatment with JAK inhibitors\n* Previous treatment with dupilumab\n* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and a Reduction of Greater Than or Equal to (>=) 2 Points From Baseline at Week 12","description":"IGA assessed severity of atopic dermatitis (AD) on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded scalp, palms and sole.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"36.6","spread":null},{"groupId":"OG002","value":"48.4","spread":null},{"groupId":"OG003","value":"36.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=75 Percent (%) Improvement From Baseline at Week 12","description":"EASI evaluates severity of participants with AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \\[including axillae and groin\\] and lower limbs \\[including buttocks\\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\\>0 to \\<10%), 2 (10 to \\<30%), 3 (30 to \\<50%), 4 (50 to \\<70%), 5 (70 to \\<90%) and 6 (90 to 100%). Total EASI score =0.1\\*Ah\\*(Eh+Ih+Exh+Lh) + 0.2\\*Au\\*(Eu+Iu+ExU+Lu) + 0.3\\*At\\*(Et+It+Ext+Lt) + 0.4\\*Al\\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1","spread":null},{"groupId":"OG001","value":"58.7","spread":null},{"groupId":"OG002","value":"70.3","spread":null},{"groupId":"OG003","value":"58.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least 4 Points Improvement in the Numerical Rating Scale (NRS) for Severity of Pruritus From Baseline at Day 2-15, Week 2, 4, 8, 12 and 16","description":"Participants were asked to assess their worst pruritus/itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst possible itching), where higher scores indicated greater severity.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"5.9","spread":null},{"groupId":"OG002","value":"7.4","spread":null},{"groupId":"OG003","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"8.4","spread":null},{"groupId":"OG002","value":"14.8","spread":null},{"groupId":"OG003","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"11.6","spread":null},{"groupId":"OG002","value":"18.6","spread":null},{"groupId":"OG003","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"14.2","spread":null},{"groupId":"OG002","value":"26.5","spread":null},{"groupId":"OG003","value":"9.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"15.0","spread":null},{"groupId":"OG002","value":"25.1","spread":null},{"groupId":"OG003","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"20.1","spread":null},{"groupId":"OG002","value":"28.8","spread":null},{"groupId":"OG003","value":"13.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"21.4","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"24.0","spread":null},{"groupId":"OG002","value":"34.1","spread":null},{"groupId":"OG003","value":"14.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"25.6","spread":null},{"groupId":"OG002","value":"34.3","spread":null},{"groupId":"OG003","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null},{"groupId":"OG001","value":"25.4","spread":null},{"groupId":"OG002","value":"39.5","spread":null},{"groupId":"OG003","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"25.5","spread":null},{"groupId":"OG002","value":"44.1","spread":null},{"groupId":"OG003","value":"21.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"30.6","spread":null},{"groupId":"OG002","value":"43.8","spread":null},{"groupId":"OG003","value":"23.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"31.4","spread":null},{"groupId":"OG002","value":"45.7","spread":null},{"groupId":"OG003","value":"24.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"30.4","spread":null},{"groupId":"OG002","value":"49.0","spread":null},{"groupId":"OG003","value":"26.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null},{"groupId":"OG001","value":"31.8","spread":null},{"groupId":"OG002","value":"49.1","spread":null},{"groupId":"OG003","value":"26.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":null},{"groupId":"OG001","value":"44.6","spread":null},{"groupId":"OG002","value":"59.3","spread":null},{"groupId":"OG003","value":"45.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.0","spread":null},{"groupId":"OG001","value":"47.5","spread":null},{"groupId":"OG002","value":"64.0","spread":null},{"groupId":"OG003","value":"50.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"47.5","spread":null},{"groupId":"OG002","value":"63.1","spread":null},{"groupId":"OG003","value":"54.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":null},{"groupId":"OG001","value":"47.0","spread":null},{"groupId":"OG002","value":"62.8","spread":null},{"groupId":"OG003","value":"57.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving IGA Response of Clear (0) or Almost Clear (1) and a Reduction of >=2 Points From Baseline at Week 2, 4, 8 and 16","description":"IGA assessed severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Assessment excluded sole, palms and scalp.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"15.2","spread":null},{"groupId":"OG002","value":"18.4","spread":null},{"groupId":"OG003","value":"4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"25.2","spread":null},{"groupId":"OG002","value":"31.4","spread":null},{"groupId":"OG003","value":"18.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null},{"groupId":"OG001","value":"35.8","spread":null},{"groupId":"OG002","value":"50.7","spread":null},{"groupId":"OG003","value":"28.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"34.8","spread":null},{"groupId":"OG002","value":"47.5","spread":null},{"groupId":"OG003","value":"38.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving EASI Response >=75% Improvement From Baseline at Week 2, 4, 8 and 16","description":"EASI evaluates severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \\[including axillae and groin\\] and lower limbs \\[including buttocks\\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\\>0 to \\<10%), 2 (10 to \\<30%), 3 (30 to \\<50%), 4 (50 to \\<70%), 5 (70 to \\<90%) and 6 (90 to 100%). Total EASI score =0.1\\*Ah\\*(Eh+Ih+Exh+Lh) + 0.2\\*Au\\*(Eu+Iu+ExU+Lu) + 0.3\\*At\\*(Et+It+Ext+Lt) + 0.4\\*Al\\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"25.4","spread":null},{"groupId":"OG002","value":"30.0","spread":null},{"groupId":"OG003","value":"14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"44.6","spread":null},{"groupId":"OG002","value":"57.4","spread":null},{"groupId":"OG003","value":"38.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"67.9","spread":null},{"groupId":"OG003","value":"52.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"60.3","spread":null},{"groupId":"OG002","value":"71.0","spread":null},{"groupId":"OG003","value":"65.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving EASI Response >=50% Improvement From Baseline at Week 2, 4, 8, 12 and 16","description":"EASI evaluates severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \\[including axillae and groin\\] and lower limbs \\[including buttocks\\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\\>0 to \\<10%), 2 (10 to \\<30%), 3 (30 to \\<50%), 4 (50 to \\<70%), 5 (70 to \\<90%) and 6 (90 to 100%). Total EASI score =0.1\\*Ah\\*(Eh+Ih+Exh+Lh) + 0.2\\*Au\\*(Eu+Iu+ExU+Lu) + 0.3\\*At\\*(Et+It+Ext+Lt) + 0.4\\*Al\\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.9","spread":null},{"groupId":"OG001","value":"53.1","spread":null},{"groupId":"OG002","value":"60.5","spread":null},{"groupId":"OG003","value":"35.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null},{"groupId":"OG001","value":"73.4","spread":null},{"groupId":"OG002","value":"78.5","spread":null},{"groupId":"OG003","value":"66.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"78.9","spread":null},{"groupId":"OG002","value":"88.4","spread":null},{"groupId":"OG003","value":"77.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","spread":null},{"groupId":"OG001","value":"75.3","spread":null},{"groupId":"OG002","value":"86.3","spread":null},{"groupId":"OG003","value":"80.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null},{"groupId":"OG001","value":"81.2","spread":null},{"groupId":"OG002","value":"87.3","spread":null},{"groupId":"OG003","value":"84.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving EASI Response >=90% Improvement From Baseline at Week 2, 4, 8, 12 and 16","description":"EASI evaluates severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \\[including axillae and groin\\] and lower limbs \\[including buttocks\\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\\>0 to \\<10%), 2 (10 to \\<30%), 3 (30 to \\<50%), 4 (50 to \\<70%), 5 (70 to \\<90%) and 6 (90 to 100%). Total EASI score =0.1\\*Ah\\*(Eh+Ih+Exh+Lh) + 0.2\\*Au\\*(Eu+Iu+ExU+Lu) + 0.3\\*At\\*(Et+It+Ext+Lt) + 0.4\\*Al\\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"8.3","spread":null},{"groupId":"OG002","value":"11.2","spread":null},{"groupId":"OG003","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"20.2","spread":null},{"groupId":"OG002","value":"32.3","spread":null},{"groupId":"OG003","value":"12.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"30.6","spread":null},{"groupId":"OG002","value":"47.3","spread":null},{"groupId":"OG003","value":"24.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null},{"groupId":"OG001","value":"36.6","spread":null},{"groupId":"OG002","value":"46.1","spread":null},{"groupId":"OG003","value":"34.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"38.0","spread":null},{"groupId":"OG002","value":"48.9","spread":null},{"groupId":"OG003","value":"38.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving EASI Response =100% Improvement From Baseline at Week 2, 4, 8, 12 and 16","description":"EASI evaluates severity of participants' AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of BSA affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk \\[including axillae and groin\\] and lower limbs \\[including buttocks\\]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in body region: 0 (0%), 1 (\\>0 to \\<10%), 2 (10 to \\<30%), 3 (30 to \\<50%), 4 (50 to \\<70%), 5 (70 to \\<90%) and 6 (90 to 100%). Total EASI score =0.1\\*Ah\\*(Eh+Ih+Exh+Lh) + 0.2\\*Au\\*(Eu+Iu+ExU+Lu) + 0.3\\*At\\*(Et+It+Ext+Lt) + 0.4\\*Al\\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"4.5","spread":null},{"groupId":"OG003","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2.6","spread":null},{"groupId":"OG002","value":"7.2","spread":null},{"groupId":"OG003","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6.0","spread":null},{"groupId":"OG002","value":"11.6","spread":null},{"groupId":"OG003","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"8.1","spread":null},{"groupId":"OG002","value":"12.3","spread":null},{"groupId":"OG003","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"12.7","spread":null},{"groupId":"OG002","value":"13.6","spread":null},{"groupId":"OG003","value":"5.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Baseline to First Achieve at Least 4 Points Improvement in the Severity of Pruritus NRS","description":"Participants were asked to assess their worst pruritus/itching due to AD over the past 24 hours on an NRS scale ranged from 0 (no itching) to 10 (worst possible itching), where higher scores indicated greater severity.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"29.0","spread":null},{"groupId":"OG002","value":"13.0","spread":null},{"groupId":"OG003","value":"31.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Percentage Body Surface Area (BSA) at Week 2, 4, 8, 12 and 16","description":"4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \\* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranges from 0 to 100%, with higher values representing greater severity of AD.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":null},{"groupId":"OG001","value":"-19.5","spread":null},{"groupId":"OG002","value":"-21.4","spread":null},{"groupId":"OG003","value":"-14.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.3","spread":null},{"groupId":"OG001","value":"-26.8","spread":null},{"groupId":"OG002","value":"-30.7","spread":null},{"groupId":"OG003","value":"-24.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.2","spread":null},{"groupId":"OG001","value":"-30.3","spread":null},{"groupId":"OG002","value":"-36.4","spread":null},{"groupId":"OG003","value":"-29.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.1","spread":null},{"groupId":"OG001","value":"-31.6","spread":null},{"groupId":"OG002","value":"-37.4","spread":null},{"groupId":"OG003","value":"-32.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.6","spread":null},{"groupId":"OG001","value":"-32.9","spread":null},{"groupId":"OG002","value":"-39.0","spread":null},{"groupId":"OG003","value":"-34.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage BSA at Week 18 and 20","description":"4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \\* % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranges from 0 to 100%, with higher values representing greater severity of AD.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":"23.67"},{"groupId":"OG001","value":"20.8","spread":"22.7"},{"groupId":"OG002","value":"14.8","spread":"19.3"},{"groupId":"OG003","value":"9.8","spread":"13.6"},{"groupId":"OG004","value":"13.2","spread":"16.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"21.2"},{"groupId":"OG001","value":"16.0","spread":"19.7"},{"groupId":"OG002","value":"14.2","spread":"19.0"},{"groupId":"OG003","value":"10.3","spread":"14.2"},{"groupId":"OG004","value":"13.2","spread":"16.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Global Assessment (PtGA) at Week 2, 4, 8, 12 and 16","description":"Participant responded to the following question: \"Overall, how would you describe your Atopic Dermatitis right now?\" on a scale: 0= clear; 1= almost clear; 2= mild; 3= moderate; and 4= severe. Higher scores indicated more severity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.8","spread":null},{"groupId":"OG002","value":"-1.0","spread":null},{"groupId":"OG003","value":"-0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-1.0","spread":null},{"groupId":"OG002","value":"-1.4","spread":null},{"groupId":"OG003","value":"-1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":null},{"groupId":"OG001","value":"-1.1","spread":null},{"groupId":"OG002","value":"-1.5","spread":null},{"groupId":"OG003","value":"-1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":null},{"groupId":"OG001","value":"-1.2","spread":null},{"groupId":"OG002","value":"-1.6","spread":null},{"groupId":"OG003","value":"-1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":null},{"groupId":"OG001","value":"-1.2","spread":null},{"groupId":"OG002","value":"-1.6","spread":null},{"groupId":"OG003","value":"-1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 2, 12 and 16","description":"DLQI is a 10-item questionnaire that measures the impact of skin disease. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":null},{"groupId":"OG001","value":"-6.7","spread":null},{"groupId":"OG002","value":"-8.5","spread":null},{"groupId":"OG003","value":"-6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":null},{"groupId":"OG001","value":"-8.7","spread":null},{"groupId":"OG002","value":"-11.0","spread":null},{"groupId":"OG003","value":"-9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":null},{"groupId":"OG001","value":"-9.0","spread":null},{"groupId":"OG002","value":"-11.7","spread":null},{"groupId":"OG003","value":"-10.8","spread":null}]}]}]},{"type":"SECONDARY","title":"DLQI at Week 20","description":"DLQI is a 10-item questionnaire that measures the impact of skin disease. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"5.3"},{"groupId":"OG001","value":"5.8","spread":"5.7"},{"groupId":"OG002","value":"6.3","spread":"5.8"},{"groupId":"OG003","value":"4.3","spread":"4.7"},{"groupId":"OG004","value":"5.6","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Index Value at Week 12 and 16","description":"EQ-5D-5L: standardized participant completed questionnaire consisted of 2 components: a health state profile and an optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Responses to 5 dimensions comprised a health state/a single utility index value. E.g. if a participant responded \"no problems\" for each 5 dimensions, then health state was coded as \"11111\" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) had a unique predefined utility index value assigned to it, by EuroQol. US value sets (with all possible health states) was used for adults in the study, range from 1 to -0.109. Higher (positive) scores = better health state.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.051","spread":null},{"groupId":"OG001","value":"0.101","spread":null},{"groupId":"OG002","value":"0.127","spread":null},{"groupId":"OG003","value":"0.104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.067","spread":null},{"groupId":"OG001","value":"0.093","spread":null},{"groupId":"OG002","value":"0.133","spread":null},{"groupId":"OG003","value":"0.113","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D-5L Visual Analogue Scale (VAS) Score at Week 12 and 16","description":"EQ-5D-5L consists of two components: a health state profile and an optional VAS. EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.975","spread":null},{"groupId":"OG001","value":"11.337","spread":null},{"groupId":"OG002","value":"17.373","spread":null},{"groupId":"OG003","value":"14.939","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.840","spread":null},{"groupId":"OG001","value":"11.223","spread":null},{"groupId":"OG002","value":"16.711","spread":null},{"groupId":"OG003","value":"14.405","spread":null}]}]}]},{"type":"SECONDARY","title":"EQ-5D-5L- Index Value at Week 20","description":"EQ-5D-5L: standardized participant completed questionnaire consisted of 2 components: a health state profile and an optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Responses to 5 dimensions comprised a health state/a single utility index value. E.g. if a participant responded \"no problems\" for each 5 dimensions, then health state was coded as \"11111\" with a predefined index value to it. Every health state (coded as combination of responses on each of 5 dimensions) had a unique predefined utility index value assigned to it, by EuroQol. US value sets (with all possible health states) was used for adults in the study, range from 1 to -0.109. Higher (positive) scores = better health state.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.905","spread":"0.097"},{"groupId":"OG001","value":"0.894","spread":"0.122"},{"groupId":"OG002","value":"0.883","spread":"0.124"},{"groupId":"OG003","value":"0.917","spread":"0.109"},{"groupId":"OG004","value":"0.890","spread":"0.109"}]}]}]},{"type":"SECONDARY","title":"EQ-5D-5L- VAS Score at Week 20","description":"EQ-5D-5L consists of two components: a health state profile and an optional VAS. EQ-5D VAS was used to record a participant's rating for his/her current health-related quality of life state and captured on a vertical VAS (0-100), where 0 = worst imaginable health state and 100 = best imaginable health state.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.2","spread":"16.3"},{"groupId":"OG001","value":"78.5","spread":"20.2"},{"groupId":"OG002","value":"76.7","spread":"19.5"},{"groupId":"OG003","value":"82.1","spread":"17.1"},{"groupId":"OG004","value":"79.6","spread":"18.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety Scale at Week 12 and 16","description":"HADS: participant rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-A: sum of all 7 items resulted in score range of 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicating greater severity of anxiety.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"-1.2","spread":null},{"groupId":"OG002","value":"-1.6","spread":null},{"groupId":"OG003","value":"-1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"-1.2","spread":null},{"groupId":"OG002","value":"-2.0","spread":null},{"groupId":"OG003","value":"-1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HADS - Depression Scale at Week 12 and 16","description":"HADS: participant rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: sum of all 7 items resulted in score range of 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicating greater severity of depression symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":null},{"groupId":"OG001","value":"-1.3","spread":null},{"groupId":"OG002","value":"-1.6","spread":null},{"groupId":"OG003","value":"-1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":null},{"groupId":"OG001","value":"-1.0","spread":null},{"groupId":"OG002","value":"-1.6","spread":null},{"groupId":"OG003","value":"-1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"HADS - Anxiety Scale at Week 20","description":"HADS: participant rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-A: sum of all 7 items resulted in score range of 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicating greater severity of anxiety.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"3.2"},{"groupId":"OG001","value":"4.5","spread":"4.5"},{"groupId":"OG002","value":"4.0","spread":"3.8"},{"groupId":"OG003","value":"3.1","spread":"3.1"},{"groupId":"OG004","value":"3.7","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"HADS - Depression Scale at Week 20","description":"HADS: participant rated 14-item questionnaire. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, both of these subscales comprised of 7 items each. Each item was rated on a 4-point scale, score range from 0 to 3, where higher scores indicates more anxiety/depression symptoms. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: sum of all 7 items resulted in score range of 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicating greater severity of depression symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"3.4"},{"groupId":"OG001","value":"3.6","spread":"3.7"},{"groupId":"OG002","value":"2.8","spread":"3.2"},{"groupId":"OG003","value":"2.2","spread":"3.1"},{"groupId":"OG004","value":"2.7","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient-Oriented Eczema Measure (POEM) at Week 12 and 16","description":"POEM is a 7-item participant reported outcome (PRO) measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item is scored as following: \"no days (0)\", \"1-2 days (1)\", \"3-4 days (2)\", \"5-6 days (3)\" and \"every day (4)\". The score ranges from 0 to 28, where higher score indicated greater severity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":null},{"groupId":"OG001","value":"-9.6","spread":null},{"groupId":"OG002","value":"-12.6","spread":null},{"groupId":"OG003","value":"-10.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":null},{"groupId":"OG001","value":"-9.2","spread":null},{"groupId":"OG002","value":"-12.5","spread":null},{"groupId":"OG003","value":"-10.8","spread":null}]}]}]},{"type":"SECONDARY","title":"POEM at Week 20","description":"POEM is a 7-item participant reported outcome (PRO) measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item is scored as following: \"no days (0)\", \"1-2 days (1)\", \"3-4 days (2)\", \"5-6 days (3)\" and \"every day (4)\". The score ranges from 0 to 28, where higher score indicated greater severity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":"6.8"},{"groupId":"OG001","value":"9.6","spread":"7.8"},{"groupId":"OG002","value":"11.6","spread":"7.7"},{"groupId":"OG003","value":"8.6","spread":"7.0"},{"groupId":"OG004","value":"11.0","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) Total Score Week 1 to Week 16","description":"PSAAD is a daily participant reported symptom electronic diary. Participants rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin \\[lighter or darker\\], bleeding from skin, seeping or oozing fluid from skin \\[other than blood\\], and skin swelling). Participant had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-1.1","spread":null},{"groupId":"OG002","value":"-1.3","spread":null},{"groupId":"OG003","value":"-0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":null},{"groupId":"OG001","value":"-1.8","spread":null},{"groupId":"OG002","value":"-2.3","spread":null},{"groupId":"OG003","value":"-1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":null},{"groupId":"OG001","value":"-2.2","spread":null},{"groupId":"OG002","value":"-2.8","spread":null},{"groupId":"OG003","value":"-2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":null},{"groupId":"OG001","value":"-2.4","spread":null},{"groupId":"OG002","value":"-3.0","spread":null},{"groupId":"OG003","value":"-2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":null},{"groupId":"OG001","value":"-2.6","spread":null},{"groupId":"OG002","value":"-3.2","spread":null},{"groupId":"OG003","value":"-2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":null},{"groupId":"OG001","value":"-2.6","spread":null},{"groupId":"OG002","value":"-3.3","spread":null},{"groupId":"OG003","value":"-2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"-2.7","spread":null},{"groupId":"OG002","value":"-3.4","spread":null},{"groupId":"OG003","value":"-2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":null},{"groupId":"OG001","value":"-2.7","spread":null},{"groupId":"OG002","value":"-3.4","spread":null},{"groupId":"OG003","value":"-3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":null},{"groupId":"OG001","value":"-2.7","spread":null},{"groupId":"OG002","value":"-3.5","spread":null},{"groupId":"OG003","value":"-3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":null},{"groupId":"OG001","value":"-2.7","spread":null},{"groupId":"OG002","value":"-3.5","spread":null},{"groupId":"OG003","value":"-3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"-2.7","spread":null},{"groupId":"OG002","value":"-3.5","spread":null},{"groupId":"OG003","value":"-3.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"-2.7","spread":null},{"groupId":"OG002","value":"-3.6","spread":null},{"groupId":"OG003","value":"-3.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":null},{"groupId":"OG001","value":"-2.8","spread":null},{"groupId":"OG002","value":"-3.7","spread":null},{"groupId":"OG003","value":"-3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"-2.8","spread":null},{"groupId":"OG002","value":"-3.6","spread":null},{"groupId":"OG003","value":"-3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":null},{"groupId":"OG001","value":"-2.9","spread":null},{"groupId":"OG002","value":"-3.6","spread":null},{"groupId":"OG003","value":"-3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":null},{"groupId":"OG001","value":"-2.8","spread":null},{"groupId":"OG002","value":"-3.6","spread":null},{"groupId":"OG003","value":"-3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"PSAAD Total Score at Week 18 and 20","description":"PSAAD is a daily participant reported symptom electronic diary. Participants rated their symptoms of AD over the past 24 hours, using 11 items (itchy skin, painful skin, dry skin, flaky skin, cracked skin, bumpy skin, red skin, discolored skin \\[lighter or darker\\], bleeding from skin, seeping or oozing fluid from skin \\[other than blood\\], and skin swelling). Participant had to think about all the areas of their body affected by their skin condition and chose the number that best described their experience for each of the 11 items, from 0 (no symptoms) to 10 (extreme symptoms), higher scores signified worse skin condition. Total PSAAD score = arithmetic mean of 11 items, 0 (no symptoms) to 10 (extreme symptoms), where higher score = worse skin condition.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"1.9"},{"groupId":"OG001","value":"3.0","spread":"2.4"},{"groupId":"OG002","value":"2.2","spread":"1.9"},{"groupId":"OG003","value":"1.7","spread":"1.7"},{"groupId":"OG004","value":"1.8","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"2.0"},{"groupId":"OG001","value":"2.6","spread":"2.3"},{"groupId":"OG002","value":"2.2","spread":"1.9"},{"groupId":"OG003","value":"1.8","spread":"1.8"},{"groupId":"OG004","value":"2.0","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Scoring Atopic Dermatitis (SCORAD) Response >=50% Improvement From Baseline at Week 2, 4, 8, 12 and 16","description":"SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2,severe=3. The severity scores were summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, each of these 2 were scored by participant/caregiver using visual analogue scale (VAS) where \"0\" = no itch/no sleeplessness and \"10\" = the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\\*B/2 + C; range from 0 to 103; higher values of SCORAD=worse outcome.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"23.6","spread":null},{"groupId":"OG002","value":"38.4","spread":null},{"groupId":"OG003","value":"15.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"45.7","spread":null},{"groupId":"OG002","value":"61.6","spread":null},{"groupId":"OG003","value":"45.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":null},{"groupId":"OG001","value":"53.4","spread":null},{"groupId":"OG002","value":"71.6","spread":null},{"groupId":"OG003","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":null},{"groupId":"OG001","value":"56.8","spread":null},{"groupId":"OG002","value":"72.3","spread":null},{"groupId":"OG003","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"56.1","spread":null},{"groupId":"OG002","value":"68.8","spread":null},{"groupId":"OG003","value":"67.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SCORAD Response >=75% Improvement From Baseline at Week 2, 4, 8 12 and 16","description":"SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2,severe=3. The severity scores were summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, each of these 2 were scored by participant/caregiver using visual analogue scale (VAS) where \"0\" = no itch/no sleeplessness and \"10\" = the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\\*B/2 + C; range from 0 to 103; higher values of SCORAD=worse outcome.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"6.4","spread":null},{"groupId":"OG002","value":"8.5","spread":null},{"groupId":"OG003","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"12.4","spread":null},{"groupId":"OG002","value":"25.4","spread":null},{"groupId":"OG003","value":"7.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"19.2","spread":null},{"groupId":"OG002","value":"41.3","spread":null},{"groupId":"OG003","value":"16.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"25.6","spread":null},{"groupId":"OG002","value":"39.3","spread":null},{"groupId":"OG003","value":"26.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"26.8","spread":null},{"groupId":"OG002","value":"40.3","spread":null},{"groupId":"OG003","value":"29.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SCORAD Visual Analogue Scale (VAS) of Itch and Sleep Loss at Week 2, 4, 8 12 and 16","description":"SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2,severe=3. The severity scores were summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, each of these 2 were scored by participant/caregiver using visual analogue scale (VAS) where \"0\" = no itch/no sleeplessness and \"10\" = the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\\*B/2 + C; range from 0 to 103; higher values of SCORAD=worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":null},{"groupId":"OG001","value":"-2.9","spread":null},{"groupId":"OG002","value":"-3.7","spread":null},{"groupId":"OG003","value":"-2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":null},{"groupId":"OG001","value":"-3.7","spread":null},{"groupId":"OG002","value":"-4.6","spread":null},{"groupId":"OG003","value":"-3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-3.9","spread":null},{"groupId":"OG002","value":"-4.9","spread":null},{"groupId":"OG003","value":"-4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":null},{"groupId":"OG001","value":"-3.9","spread":null},{"groupId":"OG002","value":"-5.0","spread":null},{"groupId":"OG003","value":"-4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":null},{"groupId":"OG001","value":"-3.8","spread":null},{"groupId":"OG002","value":"-4.8","spread":null},{"groupId":"OG003","value":"-4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"-2.6","spread":null},{"groupId":"OG002","value":"-3.3","spread":null},{"groupId":"OG003","value":"-2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-3.4","spread":null},{"groupId":"OG002","value":"-4.2","spread":null},{"groupId":"OG003","value":"-3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-3.6","spread":null},{"groupId":"OG002","value":"-4.4","spread":null},{"groupId":"OG003","value":"-3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":null},{"groupId":"OG001","value":"-3.7","spread":null},{"groupId":"OG002","value":"-4.6","spread":null},{"groupId":"OG003","value":"-4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":null},{"groupId":"OG001","value":"-3.7","spread":null},{"groupId":"OG002","value":"-4.8","spread":null},{"groupId":"OG003","value":"-4.3","spread":null}]}]}]},{"type":"SECONDARY","title":"SCORAD VAS of Itch and Sleep Loss at Week 18 and 20","description":"SCORAD: scoring index for AD combining extent, severity, subjective symptoms. Extent (A): rule of 9 was used to calculate BSA affected by AD as a % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; 1% for genitals. The score for each body region was added to determine A (0-100). Severity (B): severity of each sign (erythema; edema; oozing; excoriation; skin thickening; dryness) was assessed as none=0, mild=1, moderate=2,severe=3. The severity scores were summed to give B (0-18). Subjective symptoms (C): pruritus and sleep, each of these 2 were scored by participant/caregiver using visual analogue scale (VAS) where \"0\" = no itch/no sleeplessness and \"10\" = the worst imaginable itch/sleeplessness, higher scores=worse symptoms. Scores for itch and sleeplessness were added to give 'C' (0-20). The SCORAD for an individual was calculated: A/5 + 7\\*B/2 + C; range from 0 to 103; higher values of SCORAD=worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"2.6"},{"groupId":"OG001","value":"2.7","spread":"2.2"},{"groupId":"OG002","value":"3.0","spread":"2.5"},{"groupId":"OG003","value":"2.3","spread":"2.2"},{"groupId":"OG004","value":"2.7","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"2.4"},{"groupId":"OG001","value":"2.6","spread":"2.4"},{"groupId":"OG002","value":"3.2","spread":"2.6"},{"groupId":"OG003","value":"2.3","spread":"2.3"},{"groupId":"OG004","value":"2.8","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"2.3"},{"groupId":"OG001","value":"2.3","spread":"2.3"},{"groupId":"OG002","value":"2.1","spread":"2.3"},{"groupId":"OG003","value":"1.6","spread":"2.1"},{"groupId":"OG004","value":"1.8","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.2"},{"groupId":"OG001","value":"2.0","spread":"2.3"},{"groupId":"OG002","value":"2.4","spread":"2.6"},{"groupId":"OG003","value":"1.5","spread":"2.1"},{"groupId":"OG004","value":"1.7","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Least Square Mean of Number of Steroid-free Days From Baseline up to Week 16","description":"Number of days when a corticosteroid as a concomitant medication was not used up to Week 16 is reported as Least square mean in this outcome measure.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":null},{"groupId":"OG001","value":"30.2","spread":null},{"groupId":"OG002","value":"33.6","spread":null},{"groupId":"OG003","value":"28.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":131},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Nausea","Acne"]}}}